In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
Digitalization is playing an increasingly important role in drug-development and commercialization, but how about in new products themselves? Are digital medicines the wave of the future or an interesting, but far-reaching possibility?
Digital...
It has been four years this week (June 23, 2016) since UK voters approved a referendum for the UK to exit the EU (i.e., Brexit). Whether the UK will have a deal or not in forming its future relationship with the EU is still on the negotiating table...
How was the global pharmaceutical industry performing before the novel coronavirus (COVID-19) pandemic, and what now is the near- and long-term impact on industry fundamentals and growth projections? An upcoming DCAT webinar, presented by Graham...
Emerging pharma companies play an important role in new product development. Which companies are making strong plays based on recent high-value partnering deals? DCAT Value Chain Insights' Top 10 highlights the rising players.
Emerging pharma...
The biopharma industry, both biopharmaceutical/pharmaceutical companies and CDMOs/CMOS, has been a target of increased investment by private-equity (PE) firms. A recent analysis by Bain & Company examines financing trends and investments by PE...
CDMOs have met the operational challenges presented by the novel coronavirus (COVID-19) pandemic to date, but what is the near-term and long-term impact as biopharma companies re-access drug-development projects?
The novel coronavirus pandemic has...
Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh, discusses the importance of understanding crystallization processes to avoid unnecessary cost, risk and development delays.
Driven by growth in oncology drugs, high-potency manufacturing is an active area of investment by CDMOs/CMOs. Which CDMOs/CMOs are making investments? DCAT Value Chain Insights rounds up key recent expansions for drug substances and drug...
Immunotherapies represent a growing sector in the global oncology pharmaceutical market. Now led by Merck & Co.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), immunotherapies by Roche and AstraZeneca are joining the...
With Cambrex’s experience in combining two or more active pharmaceutical ingredients (APIs) into Fixed Dose Combination drugs (FDCs), we are the CDMO that’s expertly positioned to partner with you. Discover the benefits and challenges as we review...
